LB Pharmaceuticals Inc
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-51.6M | $-19.1M | $-3.6M | $-4.9M | $-5.3M | $-14.2M | $-27.6M | $-16.2M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | $82.0K | — | — | $79.0K | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $2.6M | — | — | $634.0K | — | — | — |
| Net Cash from Operating Activities | $-37.6M | $-23.3M | $-3.4M | $-5.6M | $-8.1M | — | — | — |
| Investing Activities | ||||||||
| Capital Expenditures | $363.0K | $32.0K | $0 | $-9.0K | $21.0K | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $-32.0K | — | — | $5.0M | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $93.8M | — | — | $0 | — | — | — |
| Net Change in Cash | — | $70.5M | — | — | $-3.1M | — | — | — |
| Free Cash Flow | $-38.0M | $-23.3M | $-3.4M | $-5.6M | $-8.1M | — | — | — |